Biomedical Engineering Reference
In-Depth Information
from chemotherapy, there is clearly bias in use of the assay. For
example, clinicians are less likely to order the test in patients who
have very favorable or very unfavorable characteristics, and more
likely to order it in situations where there is therapeutic equipoise
(e.g., node negative disease, 1-2 cm tumor, intermediate histologic
grade). For those selected to undergo testing, about 20% or more
may be spared chemotherapy. Some analyses have suggested that
use of the test is cost effective.39-41
Uncertainty remains regarding
the optimal management of patients with a mid-range RS, and a
large clinical trial has been completed that was designed to address
this issue.
39-41
References
1. Jemal A, Bray F, Center MM,
et al.
Global cancer statistics.
CA Cancer J
61: 69-90, 2011.
2. Jemal A, Siegel R, Ward E,
Clin
et al.
Cancer statistics, 2008.
CA Cancer J Clin
58: 71-96, 2008.
3. Berry DA, Cronin KA, Plevritis SK,
Effect of screening and adjuvant
therapy on mortality from breast cancer.
et al.
N Engl J Med
353: 1784-1792,
2005.
4. Hatchwell E, Greally JM: The potential role of epigenomic dysregulation
in complex human disease.
Trends Genet
23: 588-595, 2007.
5. Thompson RF, Suzuki M, Lau KW,
A pipeline for the quantitative
analysis of CG dinucleotide methylation using mass spectrometry.
Bioinformatics
et al.
25: 2164-2170, 2009.
6. Iorio MV, Casalini P, Tagliabue E,
MicroRNA profiling as a tool
to understand prognosis, therapy response and resistance in breast
cancer.
et al.
44: 2753-2759, 2008.
7. Gast MC, Schellens JH, Beijnen JH: Clinical proteomics in breast cancer:
a review.
Eur J Cancer
Breast Cancer Res Treat
116: 17-29, 2009.
8. Figueroa ME, Reimers M, Thompson RF,
An integrative genomic
and epigenomic approach for the study of transcriptional regulation.
PLoS ONE
et al.
3: e1882, 2008.
9. Ransohoff DF: Rules of evidence for cancer molecular-marker discovery
and validation.
4: 309-314, 2004.
10. Dobbin K, Simon R: Sample size determination in microarray
experiments for class comparison and prognostic classification.
Biostatistics
Nat Rev Cancer
6: 27-38, 2005.
